Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA METRAP from malaria naive to malaria-endemic populations

Molecular Therapy

Volumn 22, Issue 11, 2014, Pages 1992-2003

  Kimani, Domtila ^a   Jagne, Ya Jankey ^b   Cox, Momodou ^b   Kimani, Eva ^a   Bliss, Carly M ^c   Gitau, Evelyn ^a   Ogwang, Caroline ^a   Afolabi, Muhammed O ^b   Bowyer, Georgina ^c   Collins, Katharine A ^c   Edwards, Nick ^c   Hodgson, Susanne H ^d   Duncan, Christopher J A ^d   Spencer, Alexandra J ^c   Knight, Miguel G ^a   Drammeh, Abdoulie ^b   Anagnostou, Nicholas A ^d   Berrie, Eleanor ^c   Moyle, Sarah ^c   Gilbert, Sarah C ^c   Soipei, Peninah ^a   Okebe, Joseph ^b   Colloca, Stefano ^e   Cortese, Riccardo ^e,f   Viebig, Nicola K ^g   Roberts, Rachel ^d   Lawrie, Alison M ^d   Nicosia, Alfredo ^e,f,h   Imoukhuede, Egeruan B ^g   Bejon, Philip ^a   Chilengi, Roma ^a   Bojang, Kalifa ^b   Flanagan, Katie L ^b,i   Hill, Adrian V S ^c,d   Urban, Britta C ^a,j   Ewer, Katie J ^c   more..

^a KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^b Medical Research Council Unit   (Gambia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d CHURCHILL HOSPITAL   (United Kingdom)

^e Okairòs AG ^*  (Italy)

^f CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ MONASH UNIVERSITY   (Australia)

^j LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CHIMPANZEE ADENOVIRUS VECTOR; GAMMA INTERFERON; MODIFIED VACCINIA ANKARA; MULTI EPITOPE THROMBOSPONDIN RELATED ADHESIVE PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE; VIRUS VACCINE; MALARIA VACCINE; PROTOZOAL PROTEIN; THROMBOSPONDIN-RELATED ADHESIVE PROTEIN, PROTOZOAN;

ADULT; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DISEASE TRANSMISSION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LOW DRUG DOSE; MALARIA; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VACCINATION; CLINICAL TRIAL; ENDEMIC DISEASE; GAMBIA; GENETICS; IMMUNOLOGY; KENYA; MALARIA, FALCIPARUM; SIMIAN VIRUS; T LYMPHOCYTE; UNITED KINGDOM; VACCINIA VIRUS;

ADENOVIRUSES, SIMIAN; ADULT; ENDEMIC DISEASES; GAMBIA; GREAT BRITAIN; HUMANS; IMMUNIZATION, SECONDARY; KENYA; MALARIA VACCINES; MALARIA, FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES; VACCINIA VIRUS;

EID: 84964312968     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.109     Document Type: Article

References (38)

1. WHO (2013). World Malaria Report 2013. WHO: Geneva.
2. Noor, AM, Kinyoki, DK, Mundia, CW, Kabaria, CW, Mutua, JW, Alegana, VA et al. (2014). The changing risk of Plasmodium falciparum malaria infection in Africa: 2000-10: A spatial and temporal analysis of transmission intensity. Lancet 383: 1739-1747.
3. White, NJ, Pukrittayakamee, S, Hien, TT, Faiz, MA, Mokuolu, OA and Dondorp, AM (2014). Malaria. Lancet 383: 723-735.
4. Malaria Vaccine Funders Group. (2013). Malaria Vaccine Technology Roadmap. http://www.who.int/immunization/topics/malaria/vaccine-roadmap. Accessed 30 June 2014.
5. Kester, KE, Cummings, JF, Ofori-Anyinam, O, Ockenhouse, CF, Krzych, U, Moris, P et al.; RTS,S Vaccine Evaluation Group. (2009). Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: Safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337-346.
6. RTSS Clinical trials partnership. (2012). A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367: 2284-2295.
7. White, MT, Bejon, P, Olotu, A, Griffin, JT, Riley, EM, Kester, KE et al. (2013). The relationship between RTS,S vaccine-induced antibodies, CD4(+) T cell responses and protection against Plasmodium falciparum infection. PLoS One 8: E61395.
8. Ndungu, FM, Mwacharo, J, Kimani, D, Kai, O, Moris, P, Jongert, E et al. (2012). A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E. PLoS ONE 7: E52870.
9. Schmidt, NW, Butler, NS, Badovinac, VP and Harty, JT (2010). Extreme CD8 T cell requirements for anti-malarial liver-stage immunity following immunization with radiation attenuated sporozoites. PLoS Pathog 6: E1000998.
10. Weiss, WR and Jiang, CG (2012). Protective CD8+ T lymphocytes in primates immunized with malaria sporozoites. PLoS ONE 7: E31247.
11. Schmidt, NW, Butler, NS and Harty, JT (2009). CD8 T cell immunity to Plasmodium permits generation of protective antibodies after repeated sporozoite challenge. Vaccine 27: 6103-6106.
12. Reyes-Sandoval, A, Wyllie, DH, Bauza, K, Milicic, A, Forbes, EK, Rollier, CS et al. (2011). CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187: 1347-1357.
13. Bijker, EM, Bastiaens, GJ, Teirlinck, AC, van Gemert, GJ, Graumans, W, van de Vegte-Bolmer, M et al. (2013). Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 110: 7862-7867.
14. Birkett, AJ, Moorthy, VS, Loucq, C, Chitnis, CE and Kaslow, DC (2013). Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities. Vaccine 31 (suppl. 2): B233-B243.
15. McConkey, SJ, Reece, WH, Moorthy, VS, Webster, D, Dunachie, S, Butcher, G et al. (2003). Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
16. Webster, DP, Dunachie, S, Vuola, JM, Berthoud, T, Keating, S, Laidlaw, SM et al. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci USA 102: 4836-4841.
17. Imoukhuede, EB, Berthoud, T, Milligan, P, Bojang, K, Ismaili, J, Keating, S et al. (2006). Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men. Vaccine 24: 6526-6533.
18. Imoukhuede, EB, Andrews, L, Milligan, P, Berthoud, T, Bojang, K, Nwakanma, D et al. (2007). Low-level malaria infections detected by a sensitive polymerase chain reaction assay and use of this technique in the evaluation of malaria vaccines in an endemic area. Am J Trop Med Hyg 76: 486-493.
19. Bejon, P, Kai, OK, Mwacharo, J, Keating, S, Lang, T, Gilbert, SC et al. (2006). Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area. Eur J Immunol 36: 2264-2272.
20. Bejon, P, Mwacharo, J, Kai, O, Mwangi, T, Milligan, P, Todryk, S et al. (2006). A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA METRAP among children in Kenya. PLoS Clin Trials 1: E29.
21. O'Hara, GA, Duncan, CJ, Ewer, KJ, Collins, KA, Elias, SC, Halstead, FD et al. (2012). Clinical assessment of a recombinant simian adenovirus ChAd63: A potent new vaccine vector. J Infect Dis 205: 772-781.
22. Sheehy, SH, Duncan, CJ, Elias, SC, Collins, KA, Ewer, KJ, Spencer, AJ et al. (2011). Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 19: 2269-2276.
23. de Cassan, SC, Forbes, EK, Douglas, AD, Milicic, A, Singh, B, Gupta, P et al. (2011). The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus. J Immunol 187: 2602-2616.
24. Ewer, KJ, O'Hara, GA, Duncan, CJ, Collins, KA, Sheehy, SH, Reyes-Sandoval, A et al. (2013). Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4: 2836.
25. Ogwang, C, Afolabi, M, Kimani, D, Jagne, YJ, Sheehy, SH, Bliss, CM et al. (2013). Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA METRAP, in healthy Gambian and Kenyan adults. PLoS ONE 8: E57726.
26. Robson, KJ, Dolo, A, Hackford, IR, Doumbo, O, Richards, MB, Keita, MM et al. (1998). Natural polymorphism in the thrombospondin-related adhesive protein of Plasmodium falciparum. Am J Trop Med Hyg 58: 81-89.
27. Moorthy, VS, Imoukhuede, EB, Milligan, P, Bojang, K, Keating, S, Kaye, P et al. (2004). A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 1: E33.
28. Moorthy, VS, Pinder, M, Reece, WH, Watkins, K, Atabani, S, Hannan, C et al. (2003). Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J Infect Dis 188: 1239-1244.
29. Bejon, P, Mwacharo, J, Kai, O, Todryk, S, Keating, S, Lowe, B et al. (2007). The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum. J Immunol 179: 4193-4201.
30. Robinson, HL and Amara, RR (2005). T cell vaccines for microbial infections. Nat Med 11(suppl. 4): S25-S32.
31. Nébié, I, Edwards, NJ, Tiono, AB, Ewer, KJ, Sanou, GS, Soulama, I et al. (2014). Assessment of chimpanzee adenovirus serotype 63 neutralizing antibodies prior to evaluation of a candidate malaria vaccine regimen based on viral vectors. Clin Vaccine Immunol 21: 901-903.
32. Epstein, JE, Tewari, K, Lyke, KE, Sim, BK, Billingsley, PF, Laurens, MB et al. (2011). Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 334: 475-480.
33. Sauerwein, RW, Roestenberg, M and Moorthy, VS (2011). Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11: 57-64.
34. Wherry, EJ, Teichgräber, V, Becker, TC, Masopust, D, Kaech, SM, Antia, R et al. (2003). Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 4: 225-234.
35. Olson, JA, McDonald-Hyman, C, Jameson, SC and Hamilton, SE (2013). Effectorlike CD8(+) T cells in the memory population mediate potent protective immunity. Immunity 38: 1250-1260.
36. Jameson, SC and Masopust, D (2009). Diversity in T cell memory: An embarrassment of riches. Immunity 31: 859-871.
37. Greenwood, BM and Pickering, H (1993). A malaria control trial using insecticidetreated bed nets and targeted chemoprophylaxis in a rural area of The Gambia, west Africa. 1. A review of the epidemiology and control of malaria in The Gambia, west Africa. Trans R Soc Trop Med Hyg 87 (suppl. 2): 3-11.
38. Mwangi, TW, Ross, A, Snow, RW and Marsh, K (2005). Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 191: 1932-1939.